Physician profile
Eric J Thierman
NPI 1235101908
$4,696.22
in general payments reported to CMS, 2019-2025
33 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $529 · 2020: $265 · 2021: $540 · 2022: $810 · 2023: $853 · 2024: $987 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,528 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,527.88 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,841.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $620.58 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $288.86 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Abbvie INC. | $271.49 | 2021-2025 | Qulipta, Synthroid, Ubrelvy |
| Merck Sharp & Dohme LLC | $213.57 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Exact Sciences Corporation | $177.44 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Axsome Therapeutics, INC. | $141.82 | 2023-2025 | Auvelity |
| Astrazeneca Pharmaceuticals LP | $124.25 | 2023-2024 | Breztri, Farxiga, Airsupra |
| Phathom Pharmaceuticals, INC. | $117.93 | 2024-2025 | Voquezna |
| Amgen INC. | $98.24 | 2019-2024 | Repatha, Otezla |
| Sanofi Pasteur INC. | $81.64 | 2019-2024 | |
| Currax Pharmaceuticals LLC | $72.01 | 2023-2025 | Contrave, Nexletol, Onzetra Xsail |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.75 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $64.83 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.67 | 2021-2024 | Trintellix |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $46.94 | 2023-2025 | |
| Amarin Pharma, INC. | $46.20 | 2019-2021 | |
| Abbott Laboratories | $42.47 | 2025 | Freestyle Libre 3, Proclaim |
| Lundbeck LLC | $37.09 | 2022-2024 | Rexulti |
| Ibsa Pharma INC. | $36.45 | 2025 | Flector, Licart, Tirosint |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.61 | 2022-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $31.20 | 2022 | |
| Daiichi Sankyo INC. | $23.60 | 2022 | |
| Seqirus USA INC | $20.92 | 2025 | Flucelvax, Fluad |
| Genentech USA, INC. | $20.61 | 2019 | |
| Amneal Pharmaceuticals LLC | $17.28 | 2022 | |
| Cranial Technologies, INC | $15.23 | 2025 | Doc Band |
| E.R. Squibb & Sons, L.L.C. | $14.45 | 2020 | |
| Jazz Pharmaceuticals INC. | $14.30 | 2022 | |
| Kaleo, INC. | $13.84 | 2021 | |
| Allergan, INC. | $13.43 | 2020 | |
| Hikma Pharmaceuticals USA | $12.79 | 2023 | Ryaltris |
| Paratek Pharmaceuticals, INC. | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Thierman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.